^
    24h
    Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    2d
    CD22 Redirected Autologous T Cells for ALL (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD22 (CD22 Molecule)
    2d
    The "Route Cause" of Methotrexate-Induced Brain Structure Changes in a Juvenile Mouse Model: Comparison of Systemic and CNS-Targeted Chemotherapy. (PubMed, Neurotoxicology)
    Comparison of systemic and intrathecal delivery routes revealed that systemic MTX had a wider impact on brain morphology than did IT MTX treatment, particularly at clinically relevant doses of IT MTX. This finding provides important insight into the mechanisms that likely underlie MTX-induced neurotoxicity and focuses potential interventions on systemic toxicity.
    Preclinical • Journal
    |
    TP63 (Tumor protein 63)
    |
    methotrexate
    3d
    PA40 B-cell lymphoblastic lymphoma in a paediatric patient. (PubMed, Br J Dermatol)
    Prognosis is influenced by age, clinical presentation and genetic abnormalities, with infants carrying KMT2A translocations facing a poorer outlook. Prompt recognition and initiation of appropriate treatment, such as the UKALL protocol, are crucial in improving outcomes for paediatric patients.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1) • PAX5 (Paired Box 5) • CD79A (CD79a Molecule) • GATA3 (GATA binding protein 3) • ARID5B (AT-Rich Interaction Domain 5B)
    3d
    PA11 Langerhans cell histiocytosis in twin girls: a case report. (PubMed, Br J Dermatol)
    One proposed mechanism for the incidence of LCH in identical twins is transfer of clonal cells in utero, as demonstrated in acute lymphoblastic leukaemia. Examination of blood spots of the twins is being arranged for investigation.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    3d
    FT819 in Subjects With B-cell Malignancies (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Fate Therapeutics | Trial primary completion date: Sep 2024 --> Jun 2025
    Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • FT819
    3d
    Autologous Bedside CD19 CAR T-cell Therapy for B-ALL (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, The General Hospital of Western Theater Command
    New P1 trial
    3d
    Prognostic significance of caspase 8 associated protein 2 (CASP8AP2) in childhood b cell acute lymphoblastic Leukemia. (PubMed, Discov Oncol)
    Higher initial CASP8AP2 gene expression was associated with favorable impact on event-free survival in pediatric ALL patients. Post-induction levels did not show similar correlation. Future larger studies are needed to confirm the favorable association and to search for other possibly related prognostic factors to further refine risk stratification.
    Journal
    |
    CASP8 (Caspase 8) • CASP8AP2 (Caspase 8 Associated Protein 2)
    4d
    Coexistence of Philadelphia Chromosome in Acute Promyelocytic Leukaemia: Two Rare Cases, with A Literature Review. (PubMed, Eur J Case Rep Intern Med)
    The rare genetic co-occurrence of t(15;17)/PML::RARA and t(9;22)/BCR::ABL1 translocations may be identified in a single patient with acute promyelocytic leukaemia (APL).Successful induction using all-trans retinoic acid (ATRA) together with imatinib achieved effective control of both leukemic clones.The patient demonstrated rapid haematologic remission and favourable clinical recovery, suggesting a positive outcome with this therapeutic approach.
    Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Chr t(15;17)
    |
    imatinib • idarubicin hydrochloride
    4d
    Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci)
    Bispecific antibodies such as blinatumomab (anti-CD19), antibody-drug conjugates like inotuzumab ozogamicin (anti-CD22), and monoclonal antibodies such as daratumumab (anti-CD38) have demonstrated efficacy in relapsed or refractory disease with improved safety profiles. The integration of targeted and immune-based therapies into conventional regimens represents a decisive step toward precision medicine, aiming to enhance survival outcomes while reducing treatment-related toxicity and improving quality of life in ALL children. This review aims to provide a comprehensive overview of the current understanding of ALL pathobiology and therapeutic approaches, with particular emphasis on the expanding role of immunotherapeutic strategies in pediatric disease.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Darzalex (daratumumab)
    4d
    CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jul 2026
    Trial completion date
    |
    Triplex (CMV-MVA vaccine)
    4d
    Long-term Follow up Local Registry Study of Kymriah in South Korea (clinicaltrials.gov)
    P=N/A, N=179, Recruiting, Novartis Pharmaceuticals | N=500 --> 179
    Enrollment change
    |
    Kymriah (tisagenlecleucel-T)